glp-1 and kidneys receptor agonists in patients with chronic kidney disease either overweight or obesity GLP-1 Therapies May Benefit MPN

Start With a Consultation Discuss your weight loss treatment options with our team by requesting a consultation using the online form, or call our office at (817) 228-4315 to schedule an appointment

Compounded drugs are custom formulations made by pharmacies and may vary in quality, safety, and effectiveness, which can increase the risk of side effects or treatment failure

In 2023, Juan P Frias and colleagues, in The Lancet, published the first phase two clinical trial of orforglipron, which investigated the use of a small-molecule oral GLP-1R agonist called orforglipron in type 2 diabetes, which can be taken at any time of the day without restrictions on food and water intake (Frias et al., 2023)

GLP-1 agonist receptors mimic this naturally occurring hormone

Product packaging may differ from images shown

Doctors may also delay starting GLP-1 treatment for people with active pancreatitis, severe kidney problems, or untreated mental health conditions until those issues are managed